免疫检查点抑制剂联合阿西替尼在未经治疗的局部晚期不可切除或转移性肾细胞癌参与者中的研究
免疫检查点抑制剂与阿昔替尼联合治疗先前未治疗的局部晚期不可切除或转移性肾细胞癌患者的随机开放标签 II 期研究
This study will evaluate the safety of tobemstomig (RO7247669) in combination with axitinib alone or with tiragolumab (anti-TIGIT) and axitinib as compared to pembrolizumab and axitinib in participants with previously untreated, unresectable locally advanced or metastatic clear-cell renal cell carcinoma (ccRCC).
研究概览
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
-
Beijing、中国、100142
- Beijing Cancer Hospital
-
Nanjing、中国、210008
- Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School
-
Tianjin、中国、300060
- Tianjin Cancer Hospital
-
-
-
-
-
Dresden、德国、01307
- Universitätsklinikum "Carl Gustav Carus"
-
Hamburg、德国、20246
- Universitätsklinikum Hamburg-Eppendorf Onkologisches Zentrum Medizinische Klinik II
-
Hanover、德国、30625
- Medizinische Hochschule Hannover
-
München、德国、81675
- Klinikum rechts der Isar der TU München
-
Nürtingen、德国、72622
- Studienpraxis Urologie
-
Ulm、德国、89081
- Universitätsklinikum Ulm
-
-
-
-
-
Avignon、法国、84918
- Institut Sainte Catherine
-
Besançon、法国、25030
- CHU Besançon - Hôpital Jean Minjoz
-
Bordeaux、法国、33075
- CHU de Bordeaux - Groupe Hospitalier Saint-André - Hopital Saint-Andre
-
Caen、法国、14076
- Centre Francois Baclesse
-
Lyon、法国、69373
- Centre Leon Berard
-
Villejuif、法国、94800
- Institut Gustave Roussy
-
-
-
-
-
Brzozów、波兰、36-200
- Szpital Specjalistyczny Podkarpacki O?rodek Onkologiczny
-
Bydgoszcz、波兰、85-796
- Centrum Onkologii im. Prof. Franciszka ?ukaszczyka
-
Krakow、波兰、31-501
- Szpital Uniwersytecki w Krakowie, Oddzia? Kliniczny Kliniki Onkologii
-
Późna、波兰、60-569
- Szpital Kliniczny im. Heliodora ?wi?cickiego UM w Poznaniu
-
-
-
-
Queensland
-
Birtinya、Queensland、澳大利亚、4575
- Sunshine Coast University Hospital
-
-
-
-
Alabama
-
Birmingham、Alabama、美国、35294
- University of Alabama at Birmingham
-
-
California
-
Orange、California、美国、92868
- UC Irvine Medical Center
-
-
Georgia
-
Atlanta、Georgia、美国、30322
- Emory University
-
-
Maryland
-
Baltimore、Maryland、美国、21287
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
-
-
Tennessee
-
Nashville、Tennessee、美国、37232
- Vanderbilt University Medical Center
-
Nashville、Tennessee、美国、37203
- SCRI Oncology Partners
-
-
Texas
-
Dallas、Texas、美国、75390-9179
- UT Southwestern Medical Center
-
-
-
-
-
London、英国、EC1A 7BE
- Barts & London School of Med
-
Manchester、英国、M2O 4BX
- Christie Hospital Nhs Trust
-
-
-
-
-
Barcelona、西班牙、08035
- Hospital Universitari Vall d'Hebron
-
Barcelona、西班牙、08025
- Hospital de la Santa Creu i Sant Pau
-
Madrid、西班牙、28034
- Hospital Universitario Ramon y Cajal
-
Madrid、西班牙、28041
- Hospital Universitario 12 de Octubre
-
Madrid、西班牙、28040
- Hospital Universitario Clínico San Carlos
-
Seville、西班牙、41013
- Hospital Universitario Virgen del Rocio
-
Valencia、西班牙、46026
- Hospital Universitari i Politecnic La Fe
-
-
Cordoba
-
Córdoba、Cordoba、西班牙、14004
- Hospital Universitario Reina Sofia
-
-
-
-
-
Goyang-si、韩国、10408
- National Cancer Center
-
Jeollanam-do、韩国、58128
- Chonnam National University Hwasun Hospital
-
Seoul、韩国、05505
- Asan Medical Center
-
Seoul、韩国、06351
- Samsung Medical Center
-
Seoul、韩国、03722
- Severance Hospital, Yonsei University Health System
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1
- International Metastatic RCC Database Consortium (IMDC) risk intermediate (score of 1 or 2) or poor (score of 3-6)
- Measurable disease with at least one measurable lesion
- Histologically confirmed ccRCC with or without sarcomatoid features
- Negative for HIV, hepatitis B, or hepatitis C virus (HCV)
Exclusion Criteria:
- Pregnant or breastfeeding, or intention of becoming pregnant during the study or within 90 days after the final dose of tiragolumab, 4 months after the final dose of tobemstomig (RO7249669) and pembrolizumab, or for 1 week after the final dose of axitinib, whichever occurs last
- Inability to swallow a tablet or malabsorption syndrome
- Prior treatment for localized and/or metastatic RCC with systemic RCC-directed therapy, including T-cell costimulating or immune checkpoint blockade therapies
- Ongoing use or anticipated need for treatment with a strong CYP3A4/5 inhibitor or inducer
- Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study
- Uncontrolled or symptomatic hypercalcemia or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab
- Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
- History of leptomeningeal disease
- Uncontrolled tumor-related pain
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
- Moderate to severe hepatic impairment (Child-Pugh B or C)
- Uncontrolled hypertension
- Prior history of hypertensive crisis or hypertensive encephalopathy
- Significant cardiovascular/cerebrovascular disease within 3 months (12 months for UK participants) prior to randomization
- History of clinically significant ventricular dysrhythmias or risk factors for ventricular dysrhythmias
- History of congenital QT syndrome
- Resting heart rate (HR) > 100 bpm (or clinically significant tachycardia)
- Stroke (including transient ischemic attack), myocardial infarction, or other symptomatic ischemic event, or thromboembolic event (e.g., deep venous thrombosis [DVT], pulmonary embolism [PE]) within 3 months (12 months for UK participants) before randomization
- Significant vascular disease (e.g., aortic aneurysm or arterial dissection requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Day 1 of Cycle 1
- Tumors invading pulmonary blood vessels, cavitating pulmonary lesions or known endobronchial disease
- Tumor invading the gastrointestinal (GI) tract, including abdominal or tracheoesophageal fistulas
- Evidence of abdominal free air not explained by paracentesis or recent surgical procedure
- Active peptic ulcer disease, acute pancreatitis, acute obstruction of the pancreatic or biliary duct, appendicitis, cholangitis, cholecystitis, diverticulitis, gastric outlet obstruction
- Intra-abdominal abscess within 6 months before initiation of study treatment
- Clinical signs or symptoms of GI obstruction or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding
- Evidence of bleeding diathesis or significant coagulopathy
- Grade ≥ 3 hemorrhage or bleeding event within 28 days prior to initiation of study treatment
- Clinically significant hematuria, hematemesis, hemoptysis of > 0.5 teaspoon (2.5 mL) of red blood, coagulopathy, or other history of significant bleeding (e.g., pulmonary hemorrhage) within 3 months before initiation of study treatment
- Active or history of autoimmune disease or immune deficiency
- Treatment with systemic immunosuppressive medication within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment
- Prior allogeneic stem cell or solid organ transplantation
- History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
- History of another primary malignancy other than RCC within 2 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate > 90%)
- Administration of a live, attenuated vaccine within 4 weeks before randomization or anticipation that such a live, attenuated vaccine will be required during the study
- Active tuberculosis (TB)
- Severe infection within 4 weeks prior to initiation of study treatment
- Participants with active Epstein-Barr virus (EBV) infection or known or suspected chronic active EBV infection at screening
- Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment
- Known hypersensitivity to Chinese hamster *ovary cell products or to any component of tobemstomig, tiragolumab, pembrolizumab, or axitinib
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Arm A (Tobemstomig + Axitinib)
Participants will receive intravenous (IV) tobemstomig every three weeks (Q3W) on Day 1 of each 21-day cycle. Participants will also receive oral (PO) axitinib twice daily (BID). |
Participants will receive IV tobemstomig Q3W.
其他名称:
Participants will receive axitinib PO BID.
其他名称:
|
|
实验性的:Arm B (Tobemstomig + Tiragolumab + Axitinib)
Participants will receive IV tobemstomig followed by IV tiragolumab Q3W on Day 1 of 21-day cycle. Participants will also receive axitinib PO BID. |
Participants will receive IV tobemstomig Q3W.
其他名称:
Participants will receive axitinib PO BID.
其他名称:
Participants will receive IV tiragolumab Q3W. |
|
有源比较器:Control Arm (Pembrolizumab + Axitinib)
Participants will receive IV pembrolizumab Q3W on Day 1 of each 21-day cycle. Participants will also receive axitinib PO BID. |
Participants will receive axitinib PO BID.
其他名称:
Participants will receive IV pembrolizumab Q3W.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
不良事件的发生率和严重性(AES)
大体时间:最多2年
|
最多2年
|
合作者和调查者
调查人员
- 研究主任:Clinical Trials、Hoffmann-LaRoche
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- BO43936
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.